Skip to content
The Policy VaultThe Policy Vault

CequaHighmark

dry eye disease

Preferred products

  • cyclosporine (generic Restasis)
  • Xiidra

Initial criteria

  • age ≥ 18 years
  • diagnosis of dry eye disease (ICD-10: H04.12)
  • therapeutic failure, contraindication, or intolerance to artificial tears
  • therapeutic failure, contraindication, or intolerance to all of the following plan-preferred products, use must be verified by pharmacy claims or documented chart notes: cyclosporine (generic Restasis) AND Xiidra

Reauthorization criteria

  • prescriber attests that the member has experienced positive clinical response to therapy

Approval duration

12 months